Top

Published in:

01-04-2020 | Cholangiocarcinoma | Original paper

CD147 augmented monocarboxylate transporter-1/4 expression through modulation of the Akt-FoxO3-NF-κB pathway promotes cholangiocarcinoma migration and invasion

Authors: Paweena Dana, Saowaluk Saisomboon, Ryusho Kariya, Seiji Okada, Sumalee Obchoei, Kanlayanee Sawanyawisuth, Chaisiri Wongkham, Chawalit Pairojkul, Sopit Wongkham, Kulthida Vaeteewoottacharn

Published in: Cellular Oncology | Issue 2/2020

Abstract

Purpose

Cholangiocarcinoma (CCA) is an aggressive type of cancer. The major obstacles for treatment are its late presentation and the occurrence metastases. Targeting the metastatic process may serve as a treatment option. CD147 is a membrane protein that promotes CCA metastasis. High lactate levels in CCA are predicted to result from lactate dehydrogenase A expression and sensitivity to monocarboxylate transporter (MCT) inhibitors. An involvement of CD147 in MCT maturation has been reported, but the exact role of MCT in CCA is not clear. Here, we aimed to assess the mechanism of CD147-promoted CCA progression through MCT regulation.

Methods

The expression levels of CD147 and MCT-1/4 in human CCA tissues were determined by immunohistochemistry. Two CD147 knockout (CD147 KO) CCA cell (KKU-213) clones were established using the CRISPR/Cas9 system. Cell migration and invasion were determined using a Boyden chamber assay. Temporal protein levels were modified by siRNA, specific inhibitors and/or activators. The expression of target proteins was determined using Western blot analyses.

Results

CD147 and MCT-1/4 were found to be overexpressed in CCA tissues compared to normal bile duct tissues. In addition, we found that CD147 knockdown significantly alleviated CCA cell migration and invasion, concomitant with decreased pAkt, pFoxO3, pNF-κB (pp65) and MCT-1/4 levels. Conversely, we found that FoxO3 knockdown led to recovered migration/invasion abilities and increased pp65 and MCT-1/4 expression levels. The involvement of Akt in the regulation of MCT-1/4 expression through CD147 was established by inhibition and activation of Akt phosphorylation.

Conclusion

Our data indicate that CD147 promotes the malignant progression of CCA cells by activating the Akt-FoxO3-NF-κB-MCT-1/4 axis. As such, CD147 may serve as a possible target for advanced CCA treatment.

Available only for authorised users

B. Sripa, C. Pairojkul, Cholangiocarcinoma: Lessons from Thailand. Curr Opin Gastroenterol 24, 349–356 (2008)CrossRefPubMedPubMedCentral

N.F. Esnaola, J.E. Meyer, A. Karachristos, J.L. Maranki, E.R. Camp, C.S. Denlinger, Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer 122, 1349–1369 (2016)CrossRefPubMed

S.A. Khan, B.R. Davidson, R.D. Goldin, N. Heaton, J. Karani, S.P. Pereira, W.M. Rosenberg, P. Tait, S.D. Taylor-Robinson, A.V. Thillainayagam, H.C. Thomas, H. Wasan, G. British, Society of, guidelines for the diagnosis and treatment of cholangiocarcinoma: An update. Gut 61(1657-1669) (2012)

O. Warburg, Iron, the oxygen-carrier of respiration-ferment. Science 61, 575–582 (1925)CrossRefPubMed

G. van Niekerk, A.M. Engelbrecht, Role of PKM2 in directing the metabolic fate of glucose in cancer: A potential therapeutic target. Cell Oncol 41, 343–351 (2018)CrossRef

C. Pinheiro, A. Longatto-Filho, J. Azevedo-Silva, M. Casal, F.C. Schmitt, F. Baltazar, Role of monocarboxylate transporters in human cancers: State of the art. J Bioenerg Biomembr 44, 127–139 (2012)CrossRefPubMed

P. Kirk, M.C. Wilson, C. Heddle, M.H. Brown, A.N. Barclay, A.P. Halestrap, CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J 19, 3896–3904 (2000)CrossRefPubMedPubMedCentral

P. Fisel, E. Schaeffeler, M. Schwab, Clinical and functional relevance of the monocarboxylate transporter family in disease pathophysiology and drug therapy. Clin Transl Sci 11, 352-364 (2018)

W. Schneiderhan, M. Scheler, K.H. Holzmann, M. Marx, J.E. Gschwend, M. Bucholz, T.M. Gress, T. Seufferlein, G. Adler, F. Oswald, CD147 silencing inhibits lactate transport and reduces malignant potential of pancreatic cancer cells in in vivo and in vitro models. Gut 58, 1391–1398 (2009)CrossRefPubMed

10.

J. Hao, H. Chen, M.C. Madigan, P.J. Cozzi, J. Beretov, W. Xiao, W.J. Delprado, P.J. Russell, Y. Li, Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. Br J Cancer 103, 1008–1018 (2010)CrossRefPubMedPubMedCentral

11.

C. Biswas, Tumor cell stimulation of collagenase production by fibroblasts. Biochem Biophys Res Commun 109, 1026–1034 (1982)CrossRefPubMed

12.

Z.D. Han, X.C. Bi, W.J. Qin, H.C. He, Q.S. Dai, J. Zou, Y.K. Ye, Y.X. Liang, G.H. Zeng, Z.N. Chen, W.D. Zhong, CD147 expression indicates unfavourable prognosis in prostate cancer. Pathol Oncol Res 15, 369–374 (2009)CrossRefPubMed

13.

S. Zhu, D. Chu, Y. Zhang, X. Wang, L. Gong, X. Han, L. Yao, M. Lan, Y. Li, W. Zhang, EMMPRIN/CD147 expression is associated with disease-free survival of patients with colorectal cancer. Med Oncol 30, 369 (2013)CrossRefPubMed

14.

K.D. Curtin, I.A. Meinertzhagen, R.J. Wyman, Basigin (EMMPRIN/CD147) interacts with integrin to affect cellular architecture. J Cell Sci 118, 2649–2660 (2005)CrossRefPubMed

15.

P. Zhao, W. Zhang, S.J. Wang, X.L. Yu, J. Tang, W. Huang, Y. Li, H.Y. Cui, Y.S. Guo, J. Tavernier, S.H. Zhang, J.L. Jiang, Z.N. Chen, HAb18G/CD147 promotes cell motility by regulating annexin II-activated RhoA and Rac1 signaling pathways in hepatocellular carcinoma cells. Hepatology 54, 2012–2024 (2011)CrossRefPubMed

16.

C. Biswas, Y. Zhang, R. DeCastro, H. Guo, T. Nakamura, H. Kataoka, K. Nabeshima, The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily. Cancer Res 55, 434–439 (1995)PubMed

17.

A.P. Halestrap, M.C. Wilson, The monocarboxylate transporter family--role and regulation. IUBMB Life 64, 109–119 (2012)CrossRefPubMed

18.

P. Huang, S. Chang, X. Jiang, J. Su, C. Dong, X. Liu, Z. Yuan, Z. Zhang, H. Liao, RNA interference targeting CD147 inhibits the proliferation, invasiveness, and metastatic activity of thyroid carcinoma cells by down-regulating glycolysis. Int J Clin Exp Pathol 8, 309–318 (2015)PubMedPubMedCentral

19.

D.M. Voss, R. Spina, D.L. Carter, K.S. Lim, C.J. Jeffery, E.E. Bar, Disruption of the monocarboxylate transporter-4-basigin interaction inhibits the hypoxic response, proliferation, and tumor progression. Sci Rep 7, 4292 (2017)CrossRefPubMedPubMedCentral

20.

P. Dana, R. Kariya, K. Vaeteewoottacharn, K. Sawanyawisuth, W. Seubwai, K. Matsuda, S. Okada, S. Wongkham, Upregulation of CD147 promotes metastasis of cholangiocarcinoma by modulating the epithelial-to-mesenchymal transitional process. Oncol Res 25, 1047–1059 (2017)CrossRefPubMedPubMedCentral

21.

U. Thonsri, W. Seubwai, S. Waraasawapati, K. Sawanyawisuth, K. Vaeteewoottacharn, T. Boonmars, U. Cha'on, Overexpression of lactate dehydrogenase a in cholangiocarcinoma is correlated with poor prognosis. Histol Histopathol 32, 503–510 (2017)PubMed

22.

U. Thamrongwaranggoon, W. Seubwai, C. Phoomak, S. Sangkhamanon, U. Cha'on, T. Boonmars, S. Wongkham, Targeting hexokinase II as a possible therapy for cholangiocarcinoma. Biochem Biophys Res Commun 484, 409–415 (2017)CrossRefPubMed

23.

S. Obchoei, S.M. Weakley, S. Wongkham, C. Wongkham, K. Sawanyawisuth, Q. Yao, C. Chen, Cyclophilin a enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma. Mol Cancer 10, 102 (2011)CrossRefPubMedPubMedCentral

24.

B. Sripa, S. Leungwattanawanit, T. Nitta, C. Wongkham, V. Bhudhisawasdi, A. Puapairoj, C. Sripa, M. Miwa, Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100). World J Gastroenterol 11, 3392–3397 (2005)CrossRefPubMedPubMedCentral

25.

G. Matsumoto, J. Namekawa, M. Muta, T. Nakamura, H. Bando, K. Tohyama, M. Toi, K. Umezawa, Targeting of nuclear factor kappaB pathways by dehydroxymethylepoxyquinomicin, a novel inhibitor of breast carcinomas: Antitumor and antiangiogenic potential in vivo. Clin Cancer Res 11, 1287–1293 (2005)PubMed

26.

Y. Naito, K. Hino, H. Bono, K. Ui-Tei, CRISPRdirect: Software for designing CRISPR/Cas guide RNA with reduced off-target sites. Bioinformatics 31, 1120–1123 (2015)CrossRefPubMed

27.

L.S. Silva, L.G. Goncalves, F. Silva, G. Domingues, V. Maximo, J. Ferreira, E.W. Lam, S. Dias, A. Felix, J. Serpa, STAT3:FOXM1 and MCT1 drive uterine cervix carcinoma fitness to a lactate-rich microenvironment. Tumour Biol 37, 5385–5395 (2016)CrossRefPubMed

28.

A. Borthakur, S. Saksena, R.K. Gill, W.A. Alrefai, K. Ramaswamy, P.K. Dudeja, Regulation of monocarboxylate transporter 1 (MCT1) promoter by butyrate in human intestinal epithelial cells: Involvement of NF-kappaB pathway. J Cell Biochem 103, 1452–1463 (2008)CrossRefPubMedPubMedCentral

29.

Z. Tan, N. Xie, S. Banerjee, H. Cui, M. Fu, V.J. Thannickal, G. Liu, The monocarboxylate transporter 4 is required for glycolytic reprogramming and inflammatory response in macrophages. J Biol Chem 290, 46–55 (2015)CrossRefPubMed

30.

W. Seubwai, C. Wongkham, A. Puapairoj, N. Khuntikeo, A. Pugkhem, C. Hahnvajanawong, J. Chaiyagool, K. Umezawa, S. Okada, S. Wongkham, Aberrant expression of NF-kappaB in liver fluke associated cholangiocarcinoma: Implications for targeted therapy. PLoS One 9, e106056 (2014)CrossRefPubMedPubMedCentral

31.

M.G. Thompson, M. Larson, A. Vidrine, K. Barrios, F. Navarro, K. Meyers, P. Simms, K. Prajapati, L. Chitsike, L.M. Hellman, B.M. Baker, S.K. Watkins, FOXO3-NF-kappaB RelA protein complexes reduce Proinflammatory cell signaling and function. J Immunol 195, 5637–5647 (2015)CrossRefPubMedPubMedCentral

32.

C.Y. Sasaki, T.J. Barberi, P. Ghosh, D.L. Longo, Phosphorylation of RelA/p65 on serine 536 defines an I{kappa}B{alpha}-independent NF-{kappa}B pathway. J Biol Chem 280, 34538–34547 (2005)CrossRefPubMed

33.

G. Tzivion, M. Dobson, G. Ramakrishnan, FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochim Biophys Acta 1813, 1938–1945 (2011)CrossRefPubMed

34.

D. Hanahan, R.A. Weinberg, Hallmarks of cancer: The next generation. Cell 144, 646–674 (2011)CrossRefPubMed

35.

H. Izumi, M. Takahashi, H. Uramoto, Y. Nakayama, T. Oyama, K.Y. Wang, Y. Sasaguri, S. Nishizawa, K. Kohno, Monocarboxylate transporters 1 and 4 are involved in the invasion activity of human lung cancer cells. Cancer Sci 102, 1007–1013 (2011)CrossRefPubMed

36.

S.C. Kong, A. Nohr-Nielsen, K. Zeeberg, S.J. Reshkin, E.K. Hoffmann, I. Novak, S.F. Pedersen, Monocarboxylate transporters MCT1 and MCT4 regulate migration and invasion of pancreatic ductal adenocarcinoma cells. Pancreas 45, 1036–1047 (2016)CrossRefPubMed

37.

V. Miranda-Goncalves, M. Honavar, C. Pinheiro, O. Martinho, M.M. Pires, C. Pinheiro, M. Cordeiro, G. Bebiano, P. Costa, I. Palmeirim, R.M. Reis, F. Baltazar, Monocarboxylate transporters (MCTs) in gliomas: Expression and exploitation as therapeutic targets. Neuro-Oncology 15, 172–188 (2013)CrossRefPubMed

38.

Y. Zhang, B. Gan, D. Liu, J.H. Paik, FoxO family members in cancer. Cancer Biol Ther 12, 253–259 (2011)CrossRefPubMed

39.

N. Tanaka, M. Zhao, L. Tang, A.A. Patel, Q. Xi, H.T. Van, H. Takahashi, A.A. Osman, J. Zhang, J. Wang, J.N. Myers, G. Zhou, Gain-of-function mutant p53 promotes the oncogenic potential of head and neck squamous cell carcinoma cells by targeting the transcription factors FOXO3a and FOXM1. Oncogene 37, 1279–1292 (2017)CrossRefPubMedPubMedCentral

40.

E.L. Greer, A. Brunet, FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 24, 7410–7425 (2005)CrossRefPubMed

41.

D. Ni, X. Ma, H.Z. Li, Y. Gao, X.T. Li, Y. Zhang, Q. Ai, P. Zhang, E.L. Song, Q.B. Huang, Y. Fan, X. Zhang, Downregulation of FOXO3a promotes tumor metastasis and is associated with metastasis-free survival of patients with clear cell renal cell carcinoma. Clin Cancer Res 20, 1779–1790 (2014)CrossRefPubMed

42.

A. Brunet, A. Bonni, M.J. Zigmond, M.Z. Lin, P. Juo, L.S. Hu, M.J. Anderson, K.C. Arden, J. Blenis, M.E. Greenberg, Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857–868 (1999)CrossRefPubMed

43.

S. Yothaisong, H. Dokduang, A. Techasen, N. Namwat, P. Yongvanit, V. Bhudhisawasdi, A. Puapairoj, G.J. Riggins, W. Loilome, Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy. Tumour Biol 34, 3637–3648 (2014)CrossRef

44.

L. Luron, D. Saliba, K. Blazek, A. Lanfrancotti, I.A. Udalova, FOXO3 as a new IKK-epsilon-controlled check-point of regulation of IFN-beta expression. Eur J Immunol 42, 1030–1037 (2012)CrossRefPubMed

45.

Z. Wang, T. Yu, P. Huang, Post-translational modifications of FOXO family proteins (Review). Mol Med Rep 14, 4931–4941 (2016)CrossRefPubMed

46.

E.E. Santo, P. Stroeken, P.V. Sluis, J. Koster, R. Versteeg, E.M. Westerhout, FOXO3a is a major target of inactivation by PI3K/AKT signaling in aggressive neuroblastoma. Cancer Res 73, 2189–2198 (2013)CrossRefPubMed

47.

H. Jo, S. Mondal, D. Tan, E. Nagata, S. Takizawa, A.K. Sharma, Q. Hou, K. Shanmugasundaram, A. Prasad, J.K. Tung, A.O. Tejeda, H. Man, A.C. Rigby, H.R. Luo, Small molecule-induced cytosolic activation of protein kinase Akt rescues ischemia-elicited neuronal death. Proc Natl Acad Sci U S A 109, 10581–10586 (2012)CrossRefPubMedPubMedCentral

48.

M. Tang, Y. Zhao, N. Liu, E. Chen, Z. Quan, X. Wu, C. Luo, Overexpression of HepaCAM inhibits bladder cancer cell proliferation and viability through the AKT/FoxO pathway. J Cancer Res Clin Oncol 143, 793–805 (2017)CrossRefPubMed

49.

D. Xu, M.E. Hemler, Metabolic activation-related CD147-CD98 complex. Mol Cell Proteomics 4, 1061–1071 (2005)CrossRefPubMed

50.

F. Fei, X. Li, L. Xu, D. Li, Z. Zhang, X. Guo, H. Yang, Z. Chen, J. Xing, CD147-CD98hc complex contributes to poor prognosis of non-small cell lung cancer patients through promoting cell proliferation via the PI3K/Akt signaling pathway. Ann Surg Oncol 21, 4359–4368 (2014)CrossRefPubMed

Title: CD147 augmented monocarboxylate transporter-1/4 expression through modulation of the Akt-FoxO3-NF-κB pathway promotes cholangiocarcinoma migration and invasion
Authors: Paweena Dana
Saowaluk Saisomboon
Ryusho Kariya
Seiji Okada
Sumalee Obchoei
Kanlayanee Sawanyawisuth
Chaisiri Wongkham
Chawalit Pairojkul
Sopit Wongkham
Kulthida Vaeteewoottacharn
Publication date: 01-04-2020
Publisher: Springer Netherlands
Keywords: Cholangiocarcinoma
Cholangiocarcinoma
Published in: Cellular Oncology / Issue 2/2020
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI: https://doi.org/10.1007/s13402-019-00479-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2020

The exosomal integrin α5β1/AEP complex derived from epithelial ovarian cancer cells promotes peritoneal metastasis through regulating mesothelial cell proliferation and migration

High IGF1R protein expression correlates with disease-free survival of patients with stage III colon cancer

MicroRNA-129-5p suppresses nasopharyngeal carcinoma lymphangiogenesis and lymph node metastasis by targeting ZIC2

BRCA1-associated protein inhibits glioma cell proliferation and migration and glioma stem cell self-renewal via the TGF-β/PI3K/AKT/mTOR signalling pathway

Esophageal carcinoma: Towards targeted therapies

Long non-coding RNA LINC00858 exerts a tumor-promoting role in colon cancer via HNF4α and WNK2 regulation

Keynote webinar | Spotlight on antibody–drug conjugates in cancer